I think it will be make or brake day for NEOT:
IRVINE, Calif., Oct. 24 /PRNewswire/ -- NeoTherapeutics, Inc. (Nasdaq: NEOT - news) announced today that it will hold a conference call and webcast on Tuesday, October 30th at 10:30 a.m. (EST), 7:30 a.m. (PST), to provide an update on the Company's 521 patient pivotal study of Neotrofin in Alzheimer's disease. Alvin J. Glasky, Ph.D., Chairman and Chief Executive Officer, and Rajesh Shrotriya, M.D., President and Chief Operating Officer, will host the call.
To access the call please dial (888) 552-7850 approximately ten minutes prior to the scheduled start time. Slides used in the Company's presentation will be available on the Company's website at www.neotherapeutics.com.
A replay of the call will be available on our website at www.neotherapeutics.com.
NeoTherapeutics seeks to create value for stockholders through the discovery and development of central nervous system drugs, in-licensing and commercialization of anti-cancer drugs, and the licensing out of new drug targets discovered through genomics research. The Company has two drugs addressing major medical needs in pivotal/phase 3 stage of development: Neotrofin(TM) for Alzheimer's disease and Satraplatin for prostate cancer. Additional neurology and anti-cancer drugs such as AIT-034 and Neoquin(TM) are in phase 1 and 2 human clinical trials and the Company has a rich pipeline of pre-clinical drug candidates |
